The New Global Framework to support expansion of MDR-TB services and care
The World Health Organization (WHO) and the Stop TB Partnership (TBP) have been supporting countries to manage multidrug-resistant tuberculosis (MDR-TB) through the Green Light Committee (GLC) Initiative. The GLC Initiative was comprised of the GLC Committee, the WHO/GLC Secretariat, the Global Drug Facility, and partners who provide financial and technical assistance. During 2009-10, key stakeholders including WHO concluded that the global framework required urgent revision since expansion of access to treatment for MDR-TB is moving too slowly.
Following the endorsement by the Stop TB Partnership Coordinating Board and the WHO TB Strategic Technical Advisory Group, the implementation of the New Global Framework to support expansion of MDR-TB services and care started on 1 July 2011.
Joint meeting of the global GLC Committee and the MDR-TB Core Group, 18 -19 April 2013
The joint meeting of the global Green Light Committee (gGLC) and the Core Group of the MDR-TB Working Group was organized at the World Health Organization, Geneva from 18-19 April 2013.
The objectives and a summary of the meeting proceedings are available in the meeting report.
1st, 2nd and 3rd Meetings of the Global GLC Committee
The first, second and third meetings of the Global GLC committee were held on 6-7 October 2011, 28-29 February 2012, and 17-19 October 2012 respectively, at the World Health Organization, Geneva, Switzerland.
Mission statement: To achieve a world free of drug-resistant TB.
Goal: To accelerate scale up to achieve universal access to prevention, early diagnosis and effective patient-centred treatment for drug resistant tuberculosis by 2015
To reach this goal, the new global framework will provide:
The New Global Framework
- Increased level and diverse models of technical support from partners to assist countries to plan, implement, manage and monitor the required scale-up of MDR-TB services.
- Increased access to high-quality, affordable SLDs for the treatment of MDR-TB.
- Strengthened advocacy for the accelerated scale up of the response to MDR-TB.
- Regular and supportive monitoring and evaluation of country performance in accelerating access to MDR-TB treatment and care, to inform assessment of global progress, to propose improvements to the global, regional and national approaches, and to pursue advocacy activities tailored to country needs.
- Regular updating of international policy and guidelines relating to programmatic management of drug-resistant TB.
- Provision of advice to funding agencies, on their request, ensuring that the effective treatment of patients with MDR-TB is done in accordance with international standards.
For further information please contact: email@example.com